Home / Market News / $REGN
fiscal.ai Corporate Catalyst Impact 85/100 ● positive

FDA Approves Regeneron's Livsayis for Generalized Myasthenia Gravis

Nov 19, 2026, 3:02 AM UTC · Primary ticker $REGN

Regeneron announced FDA approval for Livsayis, its new siRNA therapy for generalized myasthenia gravis. This marks a significant milestone as it's Regeneron's first siRNA and neurology drug, offering a new, less frequent dosing option for patients.

Regeneron Pharmaceuticals received FDA approval for Livsayis (cemdisiran) to treat generalized myasthenia gravis (gMG) in adult patients. This is a significant event for Regeneron as it represents their first approved siRNA therapy and their entry into the neurology market. The drug's unique quarterly subcutaneous dosing frequency could be a competitive advantage, potentially capturing market share from existing treatments. This approval is a positive catalyst for REGN, offering a new revenue stream and diversifying its portfolio. Competitors in the gMG space, such as Alexion (AstraZeneca) with Soliris/Ultomiris and UCB with Rystiggo/Zilbrysq, may face increased competitive pressure, potentially impacting their future sales in this indication. Short-term, REGN could see a positive stock reaction, while long-term implications depend on Livsayis's market adoption and commercial success.

$REGN positive New drug approval, market expansion
$ALXN negative Increased competition in gMG market
$UCB negative Increased competition in gMG market
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.